Goldman Sachs is firmly at the top of global healthcare advisory league table as we approach the half-way point of the year, with a role on Covidien's sale meaning the bank has worked on a 70% share of deal value so far this year.

Medtronic yesterday bought Covidien in a cash-and-stock transaction at $93.22 per share, valuing the company at about $42.9 billion, a 29% premium to Covidien's closing price on Friday, according to a statement from the companies.